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Abstract  29 
There is wide recognition of a complex association between midlife hypertension and 30 
cardiovascular disease and later development of Alzheimer’s disease (AD) and cognitive 31 
impairment. While significant progress has been made in reducing rates of mortality and morbidity 32 
due to cardiovascular disease over the last thirty years, progress towards effective treatments for AD 33 
has been slower. Despite the known association between hypertension and dementia, research into 34 
each disease has largely been undertaken in parallel and independently. Yet over the last decade and 35 
a half the emergence of converging findings from pre-clinical and clinical research has shown how 36 
the renin angiotensin system (RAS), that is very important in blood pressure regulation and 37 
cardiovascular disease, warrants careful consideration in the pathogenesis of AD. Numerous 38 
components of the RAS have now been found to be altered in AD such that the multifunctional and 39 
potent vasoconstrictor angiotensin II, and similarly acting angiotensin III, are greatly altered at the 40 
expense of other RAS signalling peptides considered to contribute to neuronal and cognitive 41 
function. Collectively these changes may contribute to many of the neuropathological hallmarks of 42 
AD, as well as observed progressive deficiencies in cognitive function, whilst also linking elements 43 
of a number of the proposed hypotheses for the cause of AD. This review discusses the emergence of 44 
the RAS and its likely importance in AD, not only because of the multiple facets of its involvement, 45 
but also perhaps fortuitously because of the ready availability of numerous RAS-acting drugs, that 46 
could be repurposed as interventions in AD. 47 
 48 
49 
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Background  50 
 51 
As Journal of Alzheimer’s disease celebrates its 20th Anniversary, this timeframe has also seen the 52 
emergence of research that points strongly to the involvement of the renin angiotensin system (RAS) 53 
as a likely, fortunately already modifiable, factor in the development and pathogenesis of Alzheimer’s 54 
disease (AD; MIM 104300 (https://www.omim.org/entry/104300)). Whilst AD represents the most 55 
common form of dementia, with characteristic neuropathological hallmarks, it exists alongside a 56 
number of other causes of dementia, that have overlapping or related neuropathological processes and 57 
hallmarks. Yet, all of the causes of the various dementias still share the same damning lack of 58 
therapeutic options, that are now vital to address the ongoing and escalating health care crisis that 59 
dementia presents in an increasingly ageing population [1].   60 
A large proportion of people diagnosed with AD, have concurrent cerebrovascular disease 61 
(CVD) of variable severity, alongside the widely known characteristic AD-related amyloid-β (Aβ) 62 
pathologies like senile plaques and cerebral amyloid angiopathy (CAA), as well as tau-protein related 63 
neurofibrillary tangle pathology [2-4]. While AD shares many of the same risk factors for CVD and 64 
Vascular Cognitive Impairment (VCI), the presence of vascular risk factors or CVD exacerbates the 65 
progression, or at least lowers the clinical threshold for the manifestation, of AD [5, 6]. There seems 66 
to be a highly intimate and complex temporal relationship between the development of cardiovascular 67 
risk factors, CVD and subsequent development and/or contribution towards the pathogenesis of AD. 68 
These may also contribute to age-associated cognitive decline. Embedded within this relationship 69 
appear to be mediators of RAS function that are characteristic in blood pressure regulation and 70 
cardiovascular diseases like hypertension, but which more recently have been consistently noted to be 71 
involved in numerous pathological processes that are present in AD. 72 
This review provides an overview of the emergence of the RAS as a biochemical pathway that 73 
can have a chronic and integral role in the development and pathogenesis of AD. From initial hints of 74 
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involvement in the pre-Genome Wide Association Studies (GWAS) era of genetic association studies 75 
in AD; through to numerous consistently supportive and converging findings from numerous pre-76 
clinical studies the RAS has rose to some prominence. The concurrent emergence of supportive 77 
research findings at a population level have also helped to further elevate the RAS, as a mechanism 78 
that may explain the widely accepted, but not well understood, association between mid-life 79 
hypertension and the development of cognitive impairment and/or dementia later in life. The 80 
convergence of genetic, molecular and epidemiological evidence, and the fortunate availability of 81 
numerous drugs that work effectively to inhibit RAS activity, has now brought forth the now very 82 
credible evidence that implicates RAS involvement in AD. Fortunately, this line of research can be 83 
effectively and rapidly tested, using clinical trials of already available RAS acting drugs, in early and 84 
mid-phase clinical trials for AD.  85 
 86 
Hypotheses of Alzheimer’s disease – the parable of the blind monks and the elephant 87 
The neuropathological characterisation of AD relates to assessment of the presence of intracellular 88 
neurofibrillary tangles and extracellular deposition of various isoforms of A in the forms of senile 89 
plaques. Another characteristic that is common in AD, but not considered as part of the diagnosis is 90 
the deposition of A in blood vessels in the brain known as cerebral amyloid angiopathy (CAA) [4].  91 
The presence of such features in the post mortem brain tissue, considered alongside a medical history 92 
that refers to progressive memory loss and cognitive impairment, all help to provide what currently 93 
remains as the only method to obtain a confirmatory diagnosis of AD.   94 
For decades, theories on the development of AD have been based, in no small part, on the 95 
amyloid beta (Aβ) cascade hypothesis and the cholinergic hypothesis. These have both been 96 
extensively written about and updated in the intervening years.  The Aβ cascade hypothesis [7] 97 
describes the significant pathogenic contribution of Aβ peptide, derived from cleavage of the 98 
amyloid precursor protein (APP), and its accumulation in the brain as a result of imbalance between 99 
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its production and clearance [8-11]. The Aβ cascade hypothesis has been the focus of numerous 100 
recent unsuccessful but also ongoing, hopefully more successful, clinical trials of new AD therapies 101 
with the ultimate aim of reducing the levels of Aβ in the brain by various approaches (reviewed in 102 
[12, 13]). The cholinergic hypothesis [14, 15], describes the loss of the neurotransmitter 103 
acetylcholine (ACh) in the central nervous system, a major factor in the progressive cognitive 104 
decline associated with AD. The reductions in ACh are linked to reductions in levels of the ACh 105 
synthesising enzyme, choline acetyltransferase (ChAT) and the progressive neuronal loss that is seen 106 
in AD [16, 17], that gives rise to reductions in levels of nicotinic and muscarinic ACh receptors 107 
(nicotinic (nAChRs) and muscarinic (mAChRs) respectively) [15]. Importantly, most of the licenced 108 
drugs currently used to treat some of the symptoms of progressive AD are those that inhibit the 109 
breakdown of ACh by acetylcholinesterase, thereby increasing its lifespan. However, these 110 
‘acetylcholinesterase inhibitors’, are not curative since their function is to address the imbalances in 111 
ACh and not to modify or halt the progressive neuronal loss that the NMDA receptor antagonist 112 
‘memantine’, as an inhibitor of glutamate that is released during neuronal damage, was originally 113 
developed to help alleviate [15]. Ultimately, all of the currently licensed drugs for AD have a limited 114 
duration of effect because they are unable to stop the progressive nature of the neuropathology that 115 
current anti-Aβ intervention strategies seek to address [12, 13, 18]. 116 
Neither hypothesis is complete and self-contained and both have some shortcomings. There is 117 
evidence, for example, of positive and negative interactions between elements of the Aβ cascade and 118 
cholinergic hypotheses. Some evidence supports a potentially beneficial role of Aβ in regulating the 119 
uptake of choline, a vital component in ACh synthesis and degradation, and similarly mediated 120 
changes to AChE vesicular ACh transporter (VAChT) proteins to concentrate ACh into the synaptic 121 
vesicles from which they are released upon neurotransmission. There are also contrasting reports of 122 
the role of Aβ in: inhibiting rapid transport of VAChT; reduced levels and function (including 123 
signalling) of receptors of the cholinergic system; and reduced synthesis and release of ACh (for 124 
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review see [15]). Other complex and paradoxical interactions include the evidence in animal models 125 
of mAChRs influencing the processing of APP as well as Aβ related pathology, whereas activation 126 
of nAChRs and nicotine increased cleavage of APP by α-secretase to reduce levels of Aβ ([15] for 127 
review). 128 
Yet, whilst these hypotheses are perhaps the most widely known, other hypotheses have also 129 
been proposed. A few of these will be summarised given their increasing recognition and support by 130 
these examples are not exhaustive. The vascular hypothesis of AD wherein the modification of risk 131 
factors of AD and VCI could prevent, reduce or delay the onset of any consequential cognitive 132 
impairment or dementia [19]. The inflammatory hypothesis of AD seeks to explain how 133 
inflammation in response to both Aβ accumulation and tau-related pathology is most likely a major 134 
contributor to the progressive neuropathology of AD [20]. The mitochondrial cascade hypothesis 135 
proposes that gene inheritance defines an individual's normal mitochondrial function, which in turn 136 
influences rates of change in mitochondrial function over time through interactions with other 137 
inherited and environmental factors. These then act together to influence AD chronology including 138 
the initiation of any Aβ cascade [21].  Finally, the oxidative stress hypothesis describes numerous 139 
links between alterations, some due to genetic variation, in the anti-oxidant system and increased 140 
levels of oxidative damage and mitochondrial disturbances that contribute to the progression of 141 
dementia and might be a target for early intervention [22].  142 
There are elements of some of these alternative hypotheses that overlap and that are also 143 
consistent with elements of the Aβ cascade and cholinergic hypotheses. As mentioned, the latter has 144 
already given rise to some of the current therapies, however the former, whilst dominating drug 145 
development research in recent decades, has unfortunately yet to deliver a single effective treatment. 146 
The failure thus far, of Aβ-targeting interventions, has been suggested by some to be due to over-147 
reliance on considering the Aβ hypothesis as a primary causative process in AD, as a result of 148 
misinterpretation of previous findings that were originally presented as evidence in support of the Aβ 149 
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hypothesis, but that could also be interpreted in a manner that is independent of a role of Aβ in AD 150 
[23]. This would also be the interpretation of aspects of some the alternative hypotheses mentioned, 151 
however, it must also be noted that the failure to date of Aβ-targeting interventions may not be what 152 
is being targeted but when and for how long it is targeted since all end stage Clinical trials involve 153 
patients with advanced disease with arguably too short a follow-up period. Thus, timing is likely one 154 
of the most important factors in the eventual discovery of a new intervention (see below). 155 
On reflection, the various hypotheses proposed for AD echoes with the ancient parable of the 156 
blind men and the elephant. This describes a group of blind men attempting to learn about an 157 
elephant for the first time by touch and each member of the group proposing an explanation to the 158 
others for what it is, based on the individual part of the elephant’s body that they feel. This inevitably 159 
gives rise to each explanation being different from the members of the group depending on which 160 
body part was felt (e.g. legs, trunk, tail, wall, ears, tusks). Over the last 3 decades the great 161 
complexity of AD has continued to emerge and whilst fundamental questions remain as to its cause, 162 
some comfort should also be taken that there are now a number of hypotheses, a number of which 163 
have some degree of overlap with converging elements, and thus collectively will help us gain the 164 
complete understanding needed to meet one of the greatest health care challenges of our time.  165 
What continues to be a major stumbling block is the determination of the correct chronology 166 
of factors and events that give rise to AD and how these interact at a systems level to explain the 167 
progression of the disease and all the neuropathological and clinical nuances that are 168 
characteristically seen. The progress thus far provides significant hope for the potential gains to be 169 
had from wider adoption of integrative systems biology approaches, that have made substantial 170 
contributions to the progress of cancer research, to the study of AD [24]. A wider perspective of the 171 
various contributory processes in the pathogenesis of AD is more likely to allow new lines of drug 172 
discovery [24], or prompt the reconsideration of the drugs already known and used for other 173 
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conditions that could be repurposed to have greater benefit in timely studies for the prevention of 174 
treatment of AD [25]. 175 
 176 
Does time hold the key for the development and treatment of Alzheimer’s disease? 177 
Apart from the obvious and urgent need to develop treatments for AD, to try and tackle the 178 
escalating health care costs associated with the high prevalence in what is an increasingly aged 179 
population [1], it has become apparent that ‘timing’ is likely one of the most important factors in 180 
achieving success at preventing or effectively treating AD.  181 
It is now widely recognised that the insidious development of AD also involves a lengthy 182 
‘incubation’ period. Indeed by the time typical clinical symptoms of memory loss and cognitive 183 
impairment are apparent there is already advanced disease that could be some decades in 184 
development [26]. For a disease that is mainly described as a disease of late onset and predominantly 185 
affecting the elderly, for those people who go on to develop the disease, its earliest manifestations 186 
that are often described as changes to Aβ biology, which in turn trigger various inflammatory and 187 
oxidative mechanisms, could have occurred decades before. Thus for the majority of people that go 188 
on to develop AD, what is currently considered ‘middle age’ is likely a crucial time where the brain 189 
is at most risk towards the development of the disease [26]. 190 
Significant research has been undertaken to identify ways in which people whom might go on 191 
to develop AD can be identified as early as possible. This includes efforts to identify biomarkers 192 
such as in cerebrospinal fluid (CSF), including the measurement of isoforms Aβ and tau, or magnetic 193 
resonance imaging (MRI)-based measures of brain structure and volume, that may be of prognostic 194 
value for those still pre-symptomatic but perhaps likely to develop AD [26]. These efforts have been 195 
in parallel to thirty years of research to dissect the genetic aetiology of AD, where a plethora of risk 196 
genes have been suggested, some of which can be used to generate polygenic risk scores (PRS), with 197 
some reported accuracy to predict whom amongst people carrying various risk genes, will go on to 198 
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develop AD [27-29]. However, the genetic contribution to AD still needs to be considered alongside 199 
the important influence of lifestyle, diet and other risk factors as well as the cellular environment in 200 
which they function.  201 
It is now clear that epigenetic changes (i.e. modifications to DNA affecting their levels of 202 
activity in cells) play a likely role in AD [30], as does the regulation of gene expression by 203 
microRNAs [31], the latter field being one still very much in its development. Yet, ours and others’ 204 
early pursuits of a better understanding of the genetic aetiology of AD yielded the first hints of what 205 
might be a role of RAS in AD. This prompted wider investigations that, as a result, has now provided 206 
insights into mechanisms that may help to explain the widely known, but poorly understood 207 
association between cardiovascular disease and hypertension in particular in mid-life, and the 208 
increased risk of developing dementia in later life [32]. 209 
 210 
Humble and somewhat paradoxical beginnings 211 
Our initial curiosity as to the potential involvement of the RAS in AD arose from our own modest 212 
candidate gene association studies in the mid 1990s, in the pre-Genome Wide Association Study 213 
(GWAS) era. We sought to test whether variation in the angiotensin I-converting enzyme (ACE) 214 
gene (ACE), already implicated in cardiovascular disease [33], might also be associated with 215 
susceptibility for AD [34]. We observed a statistically significant and consistent increase in ACE (I) 216 
allele bearing genotypes and increased risk of AD, in three independent case-control cohorts, that 217 
was independent of any APOE associated risk [34]. This study, which was small by modern 218 
standards, but modestly sized in its day, coincided with two other smaller studies that found no 219 
evidence of association [35, 36]. In that pre-GWAS era, where underpowered studies were quite 220 
common, inconsistent findings were also very common [37]. Yet, unlike many of suggested AD risk 221 
genes of that time, the implicated variant (a common Alu (indel) insertion(I)/deletion (D) 222 
polymorphism (rs1799752) within intron 16) in ACE, had some functional effect and was already 223 
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known to influence plasma levels of ACE, the rate-limiting enzyme in the synthesis of the potent 224 
vasoconstrictor angiotensin II (ANGII) from angiotensin I (ANGI) [38].  225 
ACE has a complex genetic architecture, being the result of a gene duplication in antiquity 226 
but also where tracts of the gene are in very tight association whereby particular polymorphisms that 227 
occur have been reported to account for 20% of the total variation in serum ACE concentration and 228 
16-24% of the variation in ACE activity [39-44]. What had been found was that there was a linear 229 
association between the lowest plasma ACE levels in ACE I allele homozygotes, through 230 
heterozygotes and to D allele homozygotes that were associated with the highest levels of ACE [38]. 231 
Yet, there is also evidence that the ACE indel may influence the relative enzymatic contributions of 232 
the two (N- and C-) catalytic domains on ACE that give rise to ANGII [45], whilst others have 233 
reported complex negative interactions between the domains that may influence the effectiveness of 234 
ACE-inhibitors, that as their name suggests inhibit the activity of ACE and are used to treat 235 
hypertension in humans [44]. 236 
The existence of functional variants in the gene encoding an enzyme with a fundamental role 237 
in blood pressure regulation made ACE a strong candidate gene, and particularly so with additional 238 
earlier evidence of altered (increased) activity of ACE in AD in some small post mortem studies [46, 239 
47]. This line of enquiry also fitted well with the earliest inceptions of the vascular hypothesis of AD 240 
had been proposed for some years [19].  Over the subsequent decade numerous replication studies 241 
and a number of meta-analyses [48-51], including Alzgene (Gene id=125 at 242 
http://www.alzgene.org/), supported the possible modest involvement of the original variant, and 243 
other ACE variants as risk factors for AD [49, 52]. Some studies also reported associations between 244 
ACE with earlier ages of onset of AD [53]; smaller hippocampal and amygdalar volumes [54]; and 245 
lower (more adverse) levels of CSF Aβ [49]. As the GWAS era evolved, there was also supportive 246 
evidence of associations with ACE from family-based and case-control studies [55-59], in 247 
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association with CSF Aβ levels [60] and of ACE protein level (but not ACE activity) in post mortem 248 
CSF from AD patients [61].  249 
ACE currently remains a gene of interest in AD but has not surpassed the stringent 250 
significance thresholds currently used to define risk status in more recent GWAS studies [62]. Yet 251 
the story of ACE variation in AD has created some confusion. Its original candidacy in AD was 252 
based on its potential role as a determinant of vascular effects in AD. However, the risk variants of 253 
ACE found to be associated with AD were those normally associated with lower, rather than the 254 
higher levels of plasma ACE that was presumed to mediate vascular effects [33]. It was to be a few 255 
years before this apparently paradoxical finding, might be explained by some unexpected but 256 
particularly important data that was to emerge from a series of preclinical investigations. 257 
 258 
The complicated story of ACE and Aβ 259 
A few years after the first reported and somewhat confusing associations of ACE variation 260 
and AD risk, evidence that ACE might have a more direct role in AD pathology emerged and that 261 
may help with the interpretation of the reported ACE associations. Numerous, in vitro and cell-262 
culture based studies showed that ACE degraded Aβ [63-68]. There were conflicting conclusions 263 
regarding which amino acids in the Aβ peptide sequence that ACE cleaved, however collectively the 264 
data provided evidence that ACE degraded Aβ at multiple locations [11]. These data that ACE could 265 
degrade Aβ provided another way of interpreting the emerging associations between ACE variants 266 
and AD, suggesting that the associations reflected varying heritability in ACE levels and thus 267 
peoples capacity to degrade Aβ, an important requirement in Aβ clearance that is thought to 268 
contribute to the development of AD [11].  269 
In support of the in vitro studies, additional in vivo studies involving various murine 270 
chemically-induced or transgenic models of AD contributed valuable information. Early studies 271 
investigating the effect of acute and short-term ACE-inhibitor use on ACE-mediated degradation of 272 
 12 
 
Aβ in young mouse models showed no evidence of an effect on ‘steady-state’ levels of Aβ [69, 70].  273 
However, studies involving older mice and longer use of the ACE-inhibitor captopril showed 274 
elevated Aβ deposition, as well as data supporting the role of ACE in the conversion of Aβ1-42 to 275 
Aβ1-40 in both mouse and human brain homogenates whilst also giving rise to other Aβ fragments 276 
[67, 68]. Not all studies agreed on the effect of ACE-inhibitors on Aβ pathology or other negative 277 
outcome measures of AD-like pathology in experimental models. For example, studies of the ACE-278 
inhibitor perindopril, given to mice [71] and rats [72], that had received intracerebroventricular 279 
(ICV)-injections of different Aβ species (ICV-Aβ), had better cognitive outcomes than untreated 280 
animals.  Similarly, both cognitive function and cerebral blood flow improved in enalapril-treated 281 
streptozotocin (STZ)-treated diabetic rats; a rodent model proposed to simulate deficits in glucose 282 
and energy metabolism, and elevated oxidative stress, that are evident in AD [73]. Yet, enalapril also 283 
outperformed other ACE-inhibitors captopril, perindopril and lisinopril at inhibiting the potentially 284 
protective mechanism of ACE-mediated conversion of Aβ1-42 to Aβ1-40 [67]. This finding was 285 
described as a possible explanation for why enalapril was found to be associated with increased 286 
incidence of AD in a population study [74]. In contrast, 2 months of captopril exposure did not alter 287 
Aβ pathology (measures of cognition were not measured) in the triple transgenic mouse model of 288 
AD [75], nor was there any cognitive benefit in ICV-Aβ injected mice given either of the ACE-289 
inhibitors enalapril or imidapril [71].  290 
Additional, indirect, evidence of potential ACE and other RAS involvement in AD, with links 291 
to Aβ pathology amongst other things, came in studies of angiotensin type 1 receptor (AT1R) 292 
antagonists (ARAs), that do not interfere with ACE function as do ACE-inhibitors but specifically 293 
inhibit ANGII signalling. In one study the ARA candesartan improved cognitive function in STZ-294 
treated mice [76], whilst losartan [77], valsartan and telmisartan in transgenic mice [78] and in mice 295 
receiving ICV-Aβ [79] all had improved cognitive function and reduced Aβ pathology. The 296 
observations with both losartan and telmisartan are also worthy of note as both [79-81] are also 297 
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thought, as well as some other ARAs, to be metabosartans [82] that also have agonistic properties on 298 
PPAR-γ (i.e. the peroxisome proliferator-activated receptor).  299 
PPAR-γ, provides an additional interesting link between ARA function and AD because 300 
PPAR-γ activation has been implicated in the degradation and clearance of Aβ and decreases the 301 
activity of the Aβ promoting β-secretase BACE1 [83-85].  Indeed PPAR-γ has been proposed as a 302 
target for drug intervention in its own right, with drugs like rosiglitazone and pioglitazone being 303 
suggested as possible treatments for AD [86]. Yet, olmesartan, one of the ARAs that does not appear 304 
to have PPAR-γ agonist properties [85], also attenuated cerebrovascular dysfunction in the APP23 305 
mouse model of AD and improved cognitive function in transgenic mice with continuous activation 306 
of the RAS [87]. Olmesartan also had a beneficial effect on cognitive function, independent of blood 307 
pressure effects, in other mice given ICV-Aβ [88].  However, a minority of data does not support 308 
these findings. Neither eprosartan nor valsartan affected AD-like pathology (where no cognitive data 309 
was obtained) in a triple transgenic mouse model of AD [75]. 310 
Another consideration in this apparent complex interaction between ACE and Aβ, aside from 311 
the interesting PPAR-γ side-story, lies in the structure of ACE itself and its two catalytic domains 312 
(see Figure 1). Notably, the C-terminal domain of ACE is thought to be the primary domain through 313 
which ACE’s familiar role in ANGII formation is achieved, whilst the N-terminal domain is thought 314 
to be responsible for Aβ degradation as has been discussed [65, 89-91]. However, some studies 315 
suggested both domains were involved in Aβ degradation [92, 93] whilst additional findings suggest 316 
more intimate interactions between ACE and Aβ at the level of their expression. We have previously 317 
reported that ACE activity in cell culture increased following exposure of the cells to oligomeric 318 
forms of Aβ [61]. More recently our lab demonstrated that ICV-Aβ induced a progressive rise in 319 
blood pressure in Dahl salt-sensitive rats with pre-existing hypertension due to a high-salt diet. There 320 
was no change in blood pressure in similarly treated normotensive rats [94]. This study also 321 
suggested that intracerebral Aβ may exacerbate hypertension, through demonstrable modulation of 322 
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autonomic activity, suggesting that the development of AD may sometimes be a physiological 323 
response to reduced cerebral perfusion due to midlife hypertension, thus complicating the 324 
accumulation of Aβ within the brain [94]. 325 
 326 
Figure I: Human ACE-1 structure and domains specificity. 327 
Schematic representation of human ACE-1 domains structure. The two homologous domains 328 
(N-domain and C-domain) have a catalytic active zinc binding site (HExxH). The N-domain and 329 
most of C-domain are extracellular. Both domains are linked by a linker sequence (LR). 330 
Transmembrane (TM) domain joined the C-domain with an intracellular C-terminus (CT) (adapted 331 
from [89]). The figure illustrates how the N- and C-domains of ACE-1 are believed to differentially 332 
perform the reported roles of Aβ cleavage (N-domain) and more widely recognised conversion by 333 
angiotensin converting activity of angiotensin I to angiotensin II. 334 
 335 
The different roles of ACE catalytic domains on Aβ degradation, and potentially of Aβ on 336 
ACE levels of expression, may explain some of the inconsistencies observed in the various in vitro 337 
and in vivo studies undertaken thus far. Differences may also relate to some of the inconsistencies 338 
reported in vivo because of the variable affinities of different ACE-inhibitors used as tools in these 339 
studies, for each of the two ACE domains (see Table 1 for a summary). These reported differences in 340 
ACE catalytic domains amongst ACE-inhibitors likely contribute to the complex and sometimes 341 
unclear picture that has emerged over the years regarding the effect of ACE-inhibitors in various 342 
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population studies, where cognitive decline and dementia risk have been investigated and is 343 
discussed further below. 344 
Table 1: Reported specificities of ACE catalytic domains and some licensed and experimental ACE-1 345 
inhibitors: 346 
 347 
Inhibitor N-domain 
specificity 
C-domain 
specificity 
N- & C- domain 
specificity 
References 
Captopril ++ NONE + [90, 91, 95, 96] 
Lisinopril NONE ++ + [90, 91, 95, 96] 
Lisinopril-tryptophan NONE + NONE [96-98] 
Enalapril ++ NONE + [91, 95, 96] 
Ramipril NONE NONE + [96] 
*RXP407 ++ NONE NONE [95, 96, 99] 
*RXP380 NONE ++ NONE [95, 96, 99] 
     
Experimental compounds are highlighted by *. the degree of affinity is denoted by the number of +’s 348 
whilst NONE corresponds to no evidence of binding. 349 
 350 
 351 
Early evidence of AD-associated RAS changes in the Central Nervous System  352 
Prior to the ACE gene associations studies in AD, there were already a few small studies hinting at 353 
RAS changes in AD. Increased levels (although originally described as activity) of ACE the enzyme 354 
were seen in some regions of brain tissue homogenates from AD cases, that also correlated with Aβ 355 
senile plaque load, compared with control brain tissue [46]. ACE-inhibitor binding (as a measure of 356 
ACE levels) was increased in the temporal cortex of tissue from AD patients compared to controls 357 
[47]. In contrast, no significant differences were found, between AD cases and controls, in ACE 358 
activity measured in frontal cortex derived microvessels [100], or in homogenates taken from a 359 
variable number brain regions taken from AD patients [101].  360 
Other studies have examined ACE in cerebrospinal fluid (CSF) where both reduced ACE 361 
levels [102, 103] but also no differences in ACE activity or levels [104, 105] were reported in AD.  362 
In efforts to characterise RAS in AD histologically, increased neuronal and perivascular ACE 363 
immunoreactivity was found in parietal cortex tissue from AD patients [106], whilst increased 364 
ANGII and ANGII receptor (AT1R, AT2R) binding and immunoreactivity have also been found in 365 
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AD brain [103]. Whilst further study of these important RAS receptors would be very informative 366 
and timely, efforts towards this are likely to be challenging since many of the commercial antibodies 367 
currently available have now been demonstrated to be less specific than was originally thought [107, 368 
108] and thus bringing some previous findings into some doubt.  In summary, there have been a 369 
small number of studies, that provided limited but nonetheless interesting supportive data to the 370 
suggested role of RAS also found in genetic studies. The findings in many of these experimental 371 
contexts tended to be small or borderline, but so too were the sizes of many studies. The fact that 372 
numerous studies were providing similar or supportive signals that there were AD-associated 373 
changes in the RAS was sufficient for us to want to continue to pursue clearer answers to the 374 
tantalising signals that were appearing. The undertaking of larger studies was necessary. 375 
 376 
The imbalanced RAS in Alzheimer’s disease 377 
The brain has its own locally-acting (i.e. paracrine) renin-angiotensin-system (RAS) that 378 
functions independently, but also likely interacts, with the systemic RAS [109]. The RAS has been 379 
extensively detailed over the years to capture the continually gathering information that paints a 380 
picture of a system of considerable complexity where over the last decade or, more receptors and 381 
peptide agonists have been found to have numerous and sometimes unexpected functions [110, 111]. 382 
Alternate regulatory pathways have also been identified that give rise some of various metabolites of 383 
the ANGII peptide, that is probably the single most biologically important peptide in the RAS (for 384 
detailed review see [112]).  385 
In figure 2 the main elements of the RAS are presented and where for illustration purposes, 386 
some of the elements are compartmentalised to represent what is known as the ‘classical’ RAS 387 
pathway that the ‘regulatory’ RAS pathway attempts to continually counterbalance. The ‘classical’ 388 
RAS involves the conversion by the enzyme renin of angiotensinogen to angiotensin I (ANGI), that 389 
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in turn is converted to the vasoconstrictor angiotensin II (ANGII) by ACE. Within the classical RAS 390 
a delicate balance is struck between, the activation of the angiotensin II type 1 receptor (AT1R) by 391 
ANGII, the primary signalling pathway in RAS that causes vasoconstriction, which can be countered 392 
(i.e. by vasodilatation) by ANGII-mediated activation of the angiotensin II type 2 receptor (AT2R) 393 
[113]. Numerous drugs have been developed to help reduce either the production (Renin-inhibitors 394 
and ACE-inhibitors) or signalling mediated by ANGII (angiotensin receptor antagonists, ARAs) on 395 
AT1R as treatments to reduce the vasoconstrictive effects of ANGII that can help with the 396 
management of hypertension (see also figure 2). Angiotensin II can also be converted by 397 
aminopeptidase A (APA) to angiotensin III (ANGIII), and in turn to angiotensin IV (ANGIV), 398 
whereby ANGIII and ANGIV can mediate similar vasoconstrictive effects to those by ANGII, since 399 
they also bind and activate AT1R [114-117].  400 
 401 
Legend to Figure 2 402 
Summary of the RAS system, including the compartmentalisation of RAS to illustrate components 403 
that are part of the ‘Classical’ RAS and the ‘Regulatory’ RAS. The Classical RAS revolves around 404 
the production of the vasoconstrictor angiotensin II by angiotensin I-converting enzyme (ACE), and 405 
possibly angiotensin III and angiotensin IV but sequential actions of aminopeptidases-A and -N on 406 
angiotensin II and angiotensin III respectively, and resultant signalling through the angiotensin II 407 
 18 
 
type I receptor (AT1R). Signalling through AT1R is thought to be the main signalling process in 408 
RAS that increases blood pressure (denoted by the heaviest weight arrows). In contrast, stimulation 409 
of the angiotensin II type 2 receptor (AT2R), by angiotensin II serves to counteract effects of AT1R. 410 
The sites of action of currently licensed drugs, usually used for the treatment of hypertension are also 411 
indicated where Renin inhibitors and ACE inhibitors work to reduce the formation of angiotensin II, 412 
whereas angiotensin receptor antagonists serve to inhibit the binding of angiotensin II to AT1R and 413 
instead promote vasodilatory inducing stimulation of AT2R by angiotensin II. The ‘Regulatory RAS’ 414 
has a similar role to that of AT2R in working to reduce blood pressure, however this is achieved by 415 
the activity of angiotensin II converting enzyme 2 (ACE2) on angiotensin II to produce angiotensin1-416 
7 that can also bind AT2R or bind its own Mas receptor (MasR) to reduce blood pressure as 417 
indicated by the arrows. Notable but perhaps less well-known functions of the RAS are the effects, as 418 
illustrated by various peptides binding to the Insulin Regulated Aminopeptidase receptor (IRAP) (or 419 
angiotensin II type IV receptor (AT4R)), AT1R and MasR respectively on neuronal signalling 420 
pathways that can contribute to learning and memory. 421 
 422 
Collectively the pressor effects that result from ANGII, ANGIII, and perhaps ANGIV 423 
activation of AT1R are commonly considered to be the ‘classical’ actions of the RAS. The 424 
‘regulatory’ pathway in RAS is somewhat newer and while it arguably shares the same stem 425 
components as the classical RAS that includes angiotensinogen, renin and all the elements that 426 
contribute to the formation of ANGII, the main function of the regulatory RAS is the conversion by 427 
angiotensin converting enzyme 2 (ACE2) of ANGII to angiotensin 1-7 (ANG1-7). This peptide binds 428 
and activates the Mas receptor (MasR) to mediate a vasodilatory effect that counters the ‘pressor’ 429 
effected mediated through AT1R in the classical pathway [118]. Thus, the natural balance between 430 
the classical and regulatory RAS pathways is an inherent component of how blood pressure is 431 
normally regulated, and where other effects resulting from AT1R signalling (see below), are 432 
determined by the comparative activity of ACE relative to ACE2.  433 
Over the last decade our group has led a number of studies that investigated the RAS in post-434 
mortem tissue taken from people with AD and non-demented elderly to provide more data to inform 435 
the observations from various preclinical studies. Our first studies found increased ACE activity that 436 
was positively correlated with parenchymal Aβ load, as well as increased perivascular ACE 437 
immunoreactivity that was positively associated with the severity of CAA (i.e. A deposition in 438 
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blood vessels) [119].  We replicated these observations with additional measurements that took 439 
greater consideration of neuronal density, wherein ACE is normally abundant, that showed the AD-440 
associated changes to ACE were even greater than previously shown because the ACE activity was 441 
higher despite significant neuronal loss that is typical in AD patients. Furthermore, we found that the 442 
elevated ACE activity, correlated positively with the severity of tau pathology [61]. These findings 443 
led to speculation that the altered ACE activity in AD was consequential to over production of 444 
ANGII where its multifunctional effects (see below) on various pathways contributed widely to the 445 
pathogenesis of AD. In view of the other pre-clinical data suggesting the role of ACE in the 446 
degradation of A, the concurrent elevations of ACE in AD, were also seen to potentially have some 447 
beneficial effects towards reducing A burden. However our data to this point, whereby ACE 448 
activity correlated positively with parenchymal load rather than negatively as might be expected if 449 
ACE was going to have an ameliorating effect on A levels; combined with our other findings of 450 
how oligomeric forms of A increased ACE activity [61] suggested otherwise and cast some doubt 451 
as to whether in vivo in humans ACE did degrade A.  452 
Nonetheless, given the data suggesting that the brain RAS, particularly the classical pathway, 453 
was overactive in human tissue, further supported by the aforementioned findings from various in 454 
vivo models of Alzheimer’s disease (AD) (and reviewed by [120]). However, the potential role of 455 
the RAS regulatory pathway, as a potential modifier of what was assumed to be elevated ANGII 456 
levels and signalling in AD had yet to be explored.  457 
We recently showed that ACE2 activity was significantly reduced in AD in the same cohort 458 
of samples we had previously reported significant elevations in ACE [121]. The association between 459 
reduced ACE2 and AD also had stronger inverse correlations (than seen for ACE) with both 460 
parenchymal A burden and tau pathology and reduced ACE2 was also more common in people 461 
whom were carriers of the APOE epsilon 4 and ACE I alleles, that have been reported as genetic risk 462 
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factors for AD [121]. Collectively, these data, that can be summarised as a high ratio (as a proxy 463 
measure of classical RAS function) in the activity of ACE:ACE2 in AD patients compared to 464 
controls.  Until the findings of reduced ACE2 in AD, the previous findings of elevated ACE in AD 465 
not appearing to have a significant effect on A levels cast doubt as to whether ACE had a role in A 466 
degradation. However, further studies have proposed that both ACE2 and ACE can perform a 467 
sequential degradation of A, whereby ACE2 mediates the conversion of A43 to A42, which then 468 
allows ACE to further degrade A42 to A40 and some other smaller A fragments [121]. Thus, it is 469 
possible that the capacity of significantly elevated levels of ACE in AD to reduce A, at least levels 470 
of CAA where A40 is the predominant A species, is greatly limited by the reduced levels of ACE2 471 
in the brain that are required to for the first step in a sequential process [121]. Furthermore, our first 472 
empirical measurements of elevated levels of ANGII and reduced levels of its counterpart ANG1-7 473 
in human brain tissue reinforced the predominance of ANGII and AT1R signalling in the classical 474 
RAS pathway, (see figure 3) over that of the ACE2-ANG1-7-MasR regulatory pathway in AD [121].  475 
Noting that classical pathway is dominant in AD, it remained to be seen what happened 476 
downstream of ANGII formation.  Angiotensin III (ANGIII), produced from ANGII by 477 
aminopeptidase A (APA), and with the ability to mediate similar pressor effects (figure 2) to ANGII 478 
via AT1R and AT2R [122, 123] warranted investigation [114].  We found that like ANGII, ANGIII 479 
levels were increased in post mortem AD brain tissue and similarly correlated strongly with 480 
parenchymal Aβ and tau load [124]. The increased ANGIII levels in AD reinforced the 481 
predominance of the classical pathway [121] resulting not only from reduced activity of the 482 
regulatory pathway, but also due to dysregulation of the APA/APN/ANGIV/IRAP(AT4R) elements 483 
of the pathway (figure 3). This was supported by an indication of increased APA activity, and 484 
significantly reduced APN activity, thereby maintaining higher levels of ANGIII (and classical 485 
pathway signalling) through reduced conversion to ANGIV [124]. Together these data suggest that 486 
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ANGIII level, and the enzymes involved in its metabolism, may also contribute to the pathogenesis 487 
of AD. 488 
There are additional considerations to make regarding these data. We are as yet unclear as 489 
why we found the discrepancies between APA level (that was significantly reduced) and APA 490 
activity (that was elevated, although not to a level of statistical significance).  This may relate to 491 
post-translational modification of APA in AD that could change the activity of APA. We also 492 
showed that APA tended to localise within microglia surrounding Aβ plaques in AD, suggesting that 493 
certain pools of APA are recruited or produced in an immune response associated with AD 494 
pathology [124]. That the APA activity was the statistically no different between AD and controls, 495 
despite the concentration of the enzyme being significantly lower in the AD group, may reflect some 496 
compensatory changes to APA in response to the increased ANGII levels. What may also be of 497 
interest, is the ability of APA, yet another RAS enzyme, to generate from Aβ42 a highly 498 
amyloidogenic and neurotoxic N-terminal truncated and pyroglutamated (AβpE3) Aβ42 species, that 499 
in itself could also contribute directly to AD pathogenesis [125, 126].  500 
Our observed contrasting significant reduction in APN activity in AD was also supported by 501 
an apparent reduction of neuronal APN labelling in brain tissue sections, but our ELISA 502 
measurements of APN protein levels show no disease-associated differences. Importantly, reduced 503 
APN activity would reduce the levels of ANGIII conversion to ANGIV that could have important 504 
impact on downstream signalling pathways mediated by ANGIV through its receptor IRAP(AT4R) 505 
(figures 2 & 3) that has been shown to enhance learning and memory [127, 128].  506 
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 507 
Legend to Figure 3 508 
Summary of the observed changes in the RAS system in post-mortem AD brain tissue. Changes to 509 
various components of the RAS in AD means that the actions of the ‘Classical’ RAS, involving the 510 
production of angiotensins II angiotensin III by the sequential actions of angiotensin II converting 511 
enzyme (ACE), and aminopeptidases-A and -N on angiotensin I, that their subsequent activation of 512 
the angiotensin II type I receptor (AT1R) to raise blood pressure are largely preserved (denoted by 513 
the heaviest weight arrows). In contrast, the changes to preserve the classical RAS in AD do not 514 
seem extend to angiotensin IV where pressor signalling via AT1R is reduced but so is the capacity to 515 
stimulate neuronal signalling that is important to normal cognitive function. The sites where 516 
currently licensed drugs, that could be potentially used for the treatment of AD are also illustrated 517 
and noticeably present to site within the classical pathway that is overactive in AD. Renin inhibitors, 518 
work to reduce the activity of the RAS pathway as a whole, whereas ACE inhibitors work to reduce 519 
the formation of angiotensin II. The angiotensin receptor antagonists in contrast serve to inhibit the 520 
binding of angiotensin II (and other angiotensins to AT1R) to promote vasodilation through the 521 
stimulation of AT2R by angiotensin II that is also thought to be involved in cognitive function. 522 
Alzheimer’s related changes also show a clear down regulation of the ‘Regulatory RAS’ where the 523 
scope to initiate (neuronal) signalling through both AT2R and MasR is reduced, with that likely loss 524 
of function that may explain some elements of cognitive decline and that all stem from observed 525 
significant reductions in angiotensin II converting enzyme 2 (ACE2) activity seen in AD, and 526 
significant elevations (as highlighted with stronger lines) of ANGII and ANGIII and their likely 527 
increased signalling through AT1R. 528 
 529 
The collective data over our series of studies on brain RAS points to excesses of ANGII and 530 
ANGIII (figure 3) that when considered alongside pre-clinical findings could increase AD pathology. 531 
In addition, as mentioned, the diminution of ACE2 in AD, that would reduce the effectiveness of 532 
ACE2:ACE1 mediated degradation of A is also likely relevant. This has been supported in a large 533 
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independent human post-mortem series, where ARAs, that would inhibit the function of both ANGII 534 
and ANGIII, had less AD-related pathology compared with other hypertension treatment groups 535 
studied [129], and lower measures in CSF of measures of tau, but not Aβ, taken longitudinally[130]. 536 
The dysregulation of APN mediated production of ANGIV and loss of signalling that is important to 537 
memory is also relevant [127, 128], but becomes even more important when it is noted alongside 538 
data that ANG1-7 signalling via MasR also mediates long-term potentiation [131]. Thus the 539 
reductions in ACE2 and APN activity seen in AD, resulting in reduced formation of ANG1-7 and 540 
ANGIV respectively, may adversely impact on learning and memory processes (figure 3), as could 541 
the fact that high levels of ANGII and potentially ANGIII may inhibit acetycholine release [47, 132, 542 
133].  543 
 544 
Translating RAS studies at the bench to the bedside for Alzheimer’s disease 545 
There is now a convincing body of data from numerous pre-clinical investigations that 546 
support how the RAS is altered and thus is involved in the pathogenesis of AD. The challenge is now 547 
to identify if reductions of the classical RAS, that is possible through drug re-purposing approaches, 548 
may have therapeutic potential in AD [25, 134]. Fortunately, the fact that there are numerous RAS-549 
acting drugs to choose from with a lot prevailing safety data in different populations, providing 550 
significant opportunities for AD research that are not usually available when attempts to meet similar 551 
challenges are approached by drug development strategies [25].  552 
Studies conducted over two decades have consistently shown that vascular factors increase 553 
the risk of dementia and AD. Hypertension in midlife [135, 136] and late life [137, 138]; diabetes 554 
mellitus [139, 140]; arterial stiffness [141]; atrial fibrillation [142] and stroke [143] are but a few of 555 
the reported risk factors for AD. There have been conflicting conclusions [144, 145], although some 556 
of these likely relate to the methods and outcome measures studied (reviewed in [146]).  557 
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Detailed discussion of mechanisms proposed for reported associations between AD and some 558 
of these cardiovascular and metabolic syndrome factors is beyond the scope of this review, but 559 
detailed reviews are available for a number of these (hypertension [147], diabetes mellitus [148, 560 
149], arterial stiffness [150] and stroke [151, 152]), where the importance of the RAS is discussed.  561 
 562 
Involvement of RAS in the incidence and progression of Alzheimer’s disease  563 
Numerous clinical and population studies have, on the whole, provided evidence that RAS-acting 564 
drugs may outperform other anti-hypertensives in reducing the incidence of AD [74, 153-155] and 565 
the rate of progression of cognitive decline or conversion from milder forms of cognitive impairment 566 
to dementia [74, 156-163]. Similarly, there were supportive findings from meta-analyses [164, 165]; 567 
secondary investigations of dementia outcomes in hypertension trials, or measures of cognitive 568 
function in hypertensive patients taking RAS drugs [166-172]; or in AD trials of new interventions 569 
where cardiovascular medication history was also available [173-175].  Surprisingly, there have been 570 
few direct intervention trials of RAS-acting drugs in AD and these were so small N=13 [176] and 571 
N=30 [177], that the conclusions that can be drawn are naturally limited. Other studies have 572 
described how centrally-acting RAS drugs may slow rates of conversion to dementia in African-573 
Americans [178], or how the ARA candesartan outperformed lisinopril (ACE-inhibitor) and the 574 
calcium channel blocker hydrocholorothiazide [179] in executive function tests in a small, mainly 575 
Caucasian, population with mild cognitive impairment. 576 
Nonetheless, there have been conflicting results from some studies (reviewed in [180]) based 577 
on some individual population studies [181-183] or meta-analyses [184, 185], where no overall 578 
benefits for lower rates of AD or reducing cognitive decline was observed. Yet, in some studies, the 579 
grouping of all RAS drugs together (i.e. combining ARAs and ACE-inhibitors) was undertaken. From 580 
data summarised here, the combining of all RAS drugs in this way, whilst defensible from the 581 
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perspective of summarising the collective inhibition of ANGII signalling, is overly simplistic with 582 
respect to AD, particularly so until the question as to the level to which ACE degrades Aβ is clarified.  583 
 584 
Additional roles of RAS in AD pathology – beyond blood pressure in AD 585 
Data from many pre-clinical and clinical studies converge to support the potential involvement of the 586 
RAS in AD. Much of this involvement has focussed on the role of RAS, not only in terms of 587 
potential relevance to blood pressure regulation and AD risk but also towards some elements of AD 588 
pathology as has been reported in a number animal and human tissue studies. However, there 589 
remains a lack of clarity regarding whether early cerebrovascular disease is a fundamental precursor 590 
to the development of AD pathology [186]. The RAS may contribute to altered blood brain barrier 591 
(BBB) permeability and cognition [187], while ANGII-induced hypertension worsened Aβ 592 
neuropathology in a transgenic mouse model of AD [188]. Similarly, ANGII administered centrally 593 
to non-transgenic rodents, by intracerebroventricular injection, stimulated Aβ production and tau-594 
phosphorylation [189].  In contrast, an alternative question that is relevant is whether cardiovascular 595 
changes are secondary to the development of AD pathology, as has been proposed in some 596 
population studies [144]. Reports that Aβ increased ACE activity in cultured neuroblastoma cells 597 
[61]; where Aβ40 exacerbated pre-existing hypertension in rodents [94]; and where Aβ-mediated 598 
neurovascular uncoupling gave rise to the reactive oxygen species and oxidative stress that is 599 
associated with AD [190, 191] all support this possibility.  600 
A primary or secondary role for hypertension in AD is conceivable, particularly so given the 601 
often lengthy and insidious time course in the evolution of AD [26] that coincides with the 602 
emergence and rising prevalence of hypertension in populations [192, 193]. Regardless, early 603 
cerebrovascular disturbances are central to the concept of the vascular hypothesis of AD (reviewed in 604 
[194]), where it also may serve as a likely determinant of the additional development of Aβ in blood 605 
vessels of the brain, which is very common in AD [8]. Thus, intervention will likely improve any of 606 
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a number of possible aspects of the pathogenesis of AD, and the RAS, based on evidence presented, 607 
is now a credible target to try and achieve this. Yet, this story has more to offer. There is also other 608 
evidence that warrants some mention, that demonstrates an even wider involvement of RAS in AD, 609 
and in doing so further emphasises the candidacy of RAS as a pathway in which intervention could 610 
achieve some positive outcomes clinically, socially and economically.  611 
The overactive classical RAS pathway present in AD (figure 3) could cause ANGII-612 
mediated inhibition of acetycholine release, as reported in various animal and human brain tissue 613 
studies [47, 132, 133]. More recent pre-clinical studies where deficits in spatial and short-term 614 
memory mechanisms and pathological processes that require cholinergic involvement were 615 
ameliorated by RAS acting agents [195, 196]. Thus, the targeting of ANGII could not only benefit 616 
pathological mechanisms in AD mediated by Aβ and tau, but also potentially enhance cholinergic 617 
release and signalling. RAS-acting drugs may thus potentially supplement existing anti-618 
cholinesterase treatment strategies in AD. Recent findings that other receptors in RAS, namely 619 
IRAP(AT4R) that can respectively enhance learning and memory [127, 128], and MasR that 620 
mediates long-term potentiation [131], illustrates not only that AT1R signalling may be detrimental 621 
in AD, but also that the loss of activity of these other receptors is significant and presents the 622 
opportunity for further targets for intervention. 623 
As mentioned an inflammatory hypothesis has also been proposed for AD [20]. This has 624 
been the focus of a number of clinical trials in AD where the pro-inflammatory mediator TNFα has 625 
been a major focus [197]. Notably, the actions of some inflammatory mediators may be downstream 626 
effects of RAS over-activation since ANGII mediates pro- and anti-inflammatory effects, that are 627 
very prominent in AD, by activating TNFα and TGF signalling pathways respectively [198, 199]. 628 
ANGII also contributes to BBB maintenance [200]; to cell survival via the interplay of AT1R and 629 
AT2R receptor signalling [198]; and to calcium signalling that is also relevant to the pathogenesis of 630 
AD [201-203]. Thus, there are a number of other important processes that are all additionally 631 
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relevant to the pathogenesis of AD, and where an overactive RAS could contribute to, clearly 632 
reinforcing the case for RAS blockers to be considered as possible interventions for AD.  633 
 634 
Unresolved issues in the angiotensin hypothesis of AD – future research needs.  635 
There are a number of important unresolved issues that warrant further investigation.  636 
(A) Does ACE degrade Aβ?  One of the most important issues to clarify is whether ACE degrades 637 
Aβ and if so, what might be the consequences of current widespread prescription of ACE-inhibitors 638 
as a frontline treatment for hypertension. There is already evidence that only the N-domain catalytic 639 
site on ACE is responsible for Aβ cleavage, however, there are also conflicting reports of the extent 640 
to which different ACE-inhibitors bind to the ACE catalytic domains (table 1). Until this question is 641 
resolved, involving more systematic study of ACE-inhibitors in relation to AD pathology, it is 642 
possible that a subset of ACE-inhibitors, whilst acting to reduce blood pressure in people with 643 
hypertension, represent modifiable risk factors (i.e. potentially avoidable) for the progressive 644 
accumulation of Aβ that can give rise to CAA and AD.  Such investigations could help to identify 645 
the ACE inhibitors that specifically target the C-domain catalytic site on ACE and so can continue to 646 
serve as effective treatments for hypertension that millions of people worldwide require and benefit 647 
from. In addition, it can also potentially provide some contribution towards the primary prevention of 648 
AD, since potential interference with natural Aβ-degrading mechanisms could be avoided. 649 
By tackling this issue, it will also have some bearing on the related question of where in the 650 
Aβ peptide sequence that ACE cleavage occurs.  The different locations reported to date is likely the 651 
result of different experimental approaches used (discussed in more detail in [204]) to try and 652 
determine this [63-66, 68, 92]. Clearer understanding of what, if any, subsets of ACE-inhibitors may 653 
afford some risk in AD, could also clarify which ACE-inhibitors could serve as ‘tool drugs’ in 654 
experiments to better characterise the locations and dynamics of ACE mediated degradation of Aβ.  655 
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Post-translational modifications, and in rare cases, autosomal dominant inheritance of genetic 656 
mutations in the amyloid precursor protein (APP) gene that cause a very small proportion of AD 657 
cases, coincide with or are nearby to sites on Aβ that have been reported to be the sites of ACE-658 
mediated cleavage of Aβ [66, 205, 206]. Some modifications, such as the isomerisation of Aspartate-659 
7 (Asp-7) residue, that occurs increasingly in ageing [207], and which has been found in Aβ senile 660 
plaques, may determine the levels of insolubility and oligomerization of Aβ fragments and thus the 661 
resistance of Aβ to enzymatic cleavage [66, 207-209].  662 
A more in-depth knowledge of the nature of post-translational modifications of Aβ and the 663 
impact of these on the affinity of ACE for Aβ would provide helpful clarifications on whether such 664 
modifications have any bearing on whether ACE-inhibitors interfere with Aβ cleavage and clearance 665 
mechanisms. In other words, do such modifications prevent ACE-mediated cleavage of Aβ, and thus 666 
the concerns about ACE-inhibitors become irrelevant. Unfortunately, such modifications may not be 667 
able to come to the rescue of ACE-inhibitors as there is already supportive evidence in populations 668 
where ACE-inhibitors were associated with increased hazard ratios for incidence of AD [74] and 669 
mortality [210, 211] that need to be continually borne in mind and further studied. 670 
 671 
(B) How important is the blood brain barrier in relation to RAS blocking drugs? There are 672 
conflicting findings regarding the effect of RAS-acting drugs in AD, whether they cross the BBB or 673 
not and thus ACE-inhibitors cannot be considered as interchangeable with respect to AD [212, 213]. 674 
Such concerns apply more to ACE-inhibitors than ARAs, since there is less ambiguity regarding the 675 
latter and their abilities to cross the BBB [214].  As discussed, there are supportive findings that 676 
centrally acting ACE-inhibitors (i.e. those that cross the BBB) had less cognitive decline than people 677 
taking peripherally acting ACE-inhibitors [74, 157]. Another recent study from the Alzheimer’s 678 
Disease Neuroimaging Initiative (ADNI) supports this whereby BBB penetrating ACE-inhibitors and 679 
ARAs had superior memory performance and less white matter hyperintensities volume [215]. There 680 
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have also been reports that the cognitive decline of users of peripherally acting ACE-inhibitors 681 
declined more rapidly and had a higher hazard ratio for AD incidence than people taking the 682 
centrally active ACE-inhibitors [74]. We found evidence that levels of ACE, whilst having a 683 
beneficial effect on lowering Aβ levels, may also be associated with greater vascular pathology in 684 
AD patients [216, 217]. These observations reinforce the need to clarify the true nature of ACE-685 
inhibitors and ACE catalytic domains and the potential it would bring to not only reduce ANGII 686 
formation, but also avoid interfering with ACE-mediated cleavage of Aβ. Other studies have showed 687 
variable protective benefits between ACE-inhibitors and ARAs in relation to the incidence of AD 688 
and dementia [154, 155, 210, 218], and usually ARAs are superior. The possible explanation for this 689 
being that they exclusive inhibit ANGII (and ANGIII) signalling and do not interfere with ACE 690 
activity that affords some Aβ-lowering benefit. 691 
There is a persuasive argument that ACE-inhibitors should not be considered as 692 
interchangeable in relation to risk of AD and in people with AD needing medication to treat 693 
hypertension [212]. The fact that there are conflicting reports as to the level of BBB penetration of a 694 
number of ACE-inhibitors does not help either [219-223]. There have been efforts to better 695 
understand the BBB penetrability of these compounds following oral administration [221, 224-230], 696 
however, the majority of these studies were in experimental conditions targeted to inform 697 
hypertension research, rather than AD research, where BBB integrity and progressive failure is 698 
perhaps more marked as part of AD pathogenesis [188]. In short, systematic re-examination of (at 699 
least) the more commonly used ACE-inhibitors, to determine those unlikely to interfere with ACE-700 
mediated degradation of Aβ, is now imperative. This will not least help to prioritise what ACE-701 
inhibitors that may be amenable for future study in AD as interventions, but also potentially inform 702 
revisions to current guidelines regarding prescribing approaches in the management of hypertension. 703 
 704 
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(C) To what extent is cognitive function influenced by RAS signaling? There is already evidence that 705 
ANGII (and potentially ANGIII) signaling through AT1R has an anti-cholinergic effect. The 706 
tantalizing data of ANGIV and ANG1-7 mediated effects on learning and memory and long term 707 
potentiation warrant greater study, not only in AD but also in general age-associated cognitive 708 
decline [127, 128, 131, 231] for review [232, 233]). There is also significant scope for greater 709 
understanding of the mechanisms by which AT2R activation, that may result from ARAs [234], may 710 
contribute to some of the observed protective functions discussed in this review and by others where 711 
AT2R has numerous relevant functions in neurons, including modulation of neuronal excitability and 712 
its activation of PPAR that has already been described as important in AD pathology (reviewed in 713 
[235]). 714 
 715 
The ultimate test – clinical trials of RAS blockade in AD 716 
The convergence of numerous lines of supportive evidence has now positioned the RAS as a credible 717 
target for intervention in AD, which is sorely needed to increase the currently limited therapeutic 718 
options available for AD [18]. The ultimate test will be that by clinical trial and fortunately, thanks to 719 
the readily availability of RAS acting drugs, a number of trials of varying sizes, have now 720 
commenced to explore various questions regarding the role of RAS in the development and 721 
pathology AD.  722 
The first such trial to commence and likely first to finish is the UK-based (with a recruitment 723 
target of N=228) Phase II multi-centre RADAR trial of losartan compared to placebo in hypertensive 724 
and normotensive AD patients (Study ISRCTN93682878 at 725 
http://www.isrctn.com/ISRCTN93682878) where the primary outcome is change to MRI-based 726 
measures of brain structure and volume after 12 months of treatment [32]. A similar design and sized 727 
(SARTAN-AD) Phase II trial in hypertensive AD patients will compare perindopril with telmisartan 728 
(Study NCT02085265 at https://clinicaltrials.gov/ct2/show/NCT02085265). The smaller pilot Phase I 729 
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(n=66) HEART study (Study NCT02471833 at https://clinicaltrials.gov/ct2/show/NCT02471833) 730 
will compared two doses of telmisartan against placebo for effects on CSF levels of RAS 731 
components in African Americans at increased risk of AD [236]. A similarly sized (N=72) CEDAR 732 
study (Study NCT02646982 at https://clinicaltrials.gov/ct2/show/NCT02646982) will compare the 733 
effect of candesartan and placebo on a number of cardiovascular outcome measures in people with 734 
mild cognitive impairment (MCI), while the CALIBREX study (Study NCT01984164 at 735 
https://clinicaltrials.gov/ct2/show/NCT01984164) will compare lisinopril with candesartan for 736 
effects on the primary outcome of executive function in people with hypertension and MCI. Finally, 737 
the rrAD study (Study NCT02913664 at https://clinicaltrials.gov/ct2/show/NCT02913664) will 738 
compare the effects of losartan and amlodipine in conjunction with aerobic exercise training on 739 
cognitive performance in older adults who have high risk for AD.  740 
While none of these trials are sufficiently large to provide definitive proof of RAS 741 
involvement in AD, and instead are designed to inform larger Phase III studies, they serve as the first 742 
formal gold-standard tests of RAS as a target for intervention in AD patients and also elderly with 743 
mild cognitive impairment. Thus, the findings of this new collection of important studies are eagerly 744 
awaited, not only to improve our understanding of RAS involvement in AD, but also to provide 745 
insights into the vital lessons that can be learned to enhance the study design of any future definitive 746 
trials. These would aspire to be as inclusive as possible for participants (hypertensive and 747 
normotensive), and as naturalistic as possible in terms of fitting well with standard care, as well as 748 
informing what might be the optimal diagnostic groups (e.g. AD or MCI) to include. 749 
 750 
Conclusions 751 
This review has attempted to describe what has been the maturation of the evidence that 752 
implicates the RAS in AD and gives credence to the angiotensin hypothesis for AD. Converging 753 
evidence from numerous pre-clinical and clinical lines of research into the RAS in AD may finally 754 
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explain widely reported, less well understood, associations between hypertension and AD. This is also 755 
compatible and consistent with the vascular hypothesis of AD that continues to gain support. In the 756 
last two decades, the angiotensin hypothesis has come of age from relatively spasmodic and unrelated 757 
lines of research enquiry towards more focused and sometimes increasingly larger or more rigorous 758 
studies, the findings of which have now provided sufficient evidence to justify the clinical trials that 759 
are now underway. There remain unresolved issues that warrant further and careful research but which 760 
have the potential to be impactful on a global scale in their own right. How certain hypertension 761 
treatments might require removal from normal use, and in doing so help focus in on those that have 762 
the best long-term benefits against both hypertension and the development of AD is a key example.  763 
As a researcher of RAS in AD for nearly two decades, these are genuinely exciting times with the 764 
results of ongoing clinical trials keenly awaited. The results of these trials will hopefully provide some 765 
positive results to pave the way for future Phase III trials that can exploit the plethora of readily 766 
available generic drugs, many with extensive safety data and most because they exist in generic form, 767 
will be highly economical options for publicly funded health care systems, where they can be made 768 
widely available to all patients in need.   769 
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